Lp(a) test: who should get tested and what the results mean

Q: Does high Lp(a) mean I'll definitely have a heart attack?

No. Elevated Lp(a) increases your probability of cardiovascular events, but many people with high Lp(a) live long, healthy lives — especially if they manage all other risk factors well. Conversely, some people with normal Lp(a) still have heart attacks due to other risk factors. Lp(a) is one piece of a complex puzzle. ---

One in five people carries a genetic time bomb in their blood — and most doctors never test for it.

It’s called Lp(a), or lipoprotein(a), and it’s arguably the most underdiagnosed cardiovascular risk factor in medicine. Unlike LDL cholesterol or triglycerides, your Lp(a) level is almost entirely determined by your DNA. You can’t diet it away, and standard statins don’t lower it. Yet elevated Lp(a) doubles or even triples your risk of heart attack, stroke, and aortic valve disease — silently, over decades.

The good news? A single blood test taken once in your lifetime can tell you whether you carry this risk. And for the first time in history, targeted therapies are in late-stage clinical trials. Understanding your Lp(a) may be one of the most important things you can do for your cardiovascular longevity.

What you’ll learn:

What Lp(a) is and why it matters
Who should get tested
How to interpret your results
Lp(a) and biological aging
What you can do about high Lp(a)
How SuperAge tracks your cardiovascular risk
FAQ

What is Lp(a)?

Lp(a) is a type of lipoprotein particle — essentially an LDL particle with an extra protein called apolipoprotein(a) attached to it. This additional protein makes Lp(a) stickier, more inflammatory, and more dangerous than regular LDL.

Quick definition: Lp(a) is a genetically determined lipoprotein particle that promotes plaque buildup, inflammation, and blood clotting. Elevated levels significantly increase the risk of heart attack, stroke, and aortic valve stenosis — independently of other risk factors.

The triple threat mechanism

What makes Lp(a) uniquely dangerous is that it attacks your cardiovascular system through three simultaneous pathways:

Atherosclerosis acceleration. Lp(a) particles deposit cholesterol in artery walls just like LDL — but they’re harder for the body to clear. They penetrate the arterial lining and resist normal removal mechanisms.
Chronic inflammation. The oxidized phospholipids (OxPL) carried on Lp(a) particles trigger inflammatory cascades in the vessel wall. This connects Lp(a) to the same chronic low-grade inflammation that drives biological aging.
Pro-thrombotic activity. Apolipoprotein(a) structurally resembles plasminogen — the protein your body uses to dissolve blood clots. Lp(a) competes with plasminogen, effectively inhibiting your natural clot-dissolving system. This means clots form more easily and break down more slowly.

How common is elevated Lp(a)?

Approximately 20% of the global population — roughly 1.4 billion people — have Lp(a) levels above the commonly used threshold of 50 mg/dL (125 nmol/L). Prevalence varies by ethnicity:

Population	Elevated Lp(a) prevalence
African descent	~25-30%
South Asian	~25-30%
European	~15-20%
East Asian	~10-15%
Hispanic	~10-15%

The key insight: Lp(a) is ~90% genetically determined by the LPA gene. Unlike LDL cholesterol, lifestyle factors have minimal impact on Lp(a) levels. This is why testing matters so much — you can’t guess your level from your lifestyle choices.

The science: Lp(a) and cardiovascular disease

What the evidence shows

The evidence linking Lp(a) to cardiovascular disease is now overwhelming, based on three converging lines of research:

Epidemiological studies. The Copenhagen Heart Study followed over 100,000 individuals and found that Lp(a) levels above 50 mg/dL (125 nmol/L) were associated with a 1.5-2x increased risk of myocardial infarction. At very high levels (above 180 nmol/L), the risk increased 3-4 fold.

Mendelian randomization studies. These natural genetic experiments confirm that the relationship is causal, not merely correlational. People who inherit variants producing high Lp(a) have higher cardiovascular event rates regardless of other risk factors.

Genome-wide association studies (GWAS). The LPA gene locus is consistently one of the strongest genetic signals for coronary artery disease and aortic valve calcification.

Conditions linked to elevated Lp(a)

Condition	Risk increase (elevated Lp(a))
Myocardial infarction	1.5-3x
Ischemic stroke	1.3-1.7x
Aortic valve stenosis	1.5-2.5x
Peripheral artery disease	1.3-1.5x
Heart failure	1.2-1.5x

Lp(a) vs LDL: why your standard lipid panel misses it

A standard lipid panel measures total cholesterol, LDL-C, HDL-C, and triglycerides. Here’s the problem: Lp(a) cholesterol is included in your LDL-C measurement without being separately identified. This means:

A person with “normal” LDL of 130 mg/dL (3.4 mmol/L) could actually have LDL of 100 mg/dL (2.6 mmol/L) plus 30 mg/dL (0.8 mmol/L) of Lp(a)-cholesterol — a very different risk profile
Standard LDL-lowering strategies (statins, diet) reduce the LDL portion but leave Lp(a) unchanged — or may even slightly raise it
Without a specific Lp(a) test, this hidden risk remains invisible

Who should get tested

Current guidelines

The European Atherosclerosis Society (EAS) and the European Society of Cardiology (ESC) recommend that every adult should have Lp(a) measured at least once in their lifetime. The American Heart Association and the National Lipid Association have echoed similar positions.

Priority testing recommended for

You should get tested now if any of the following apply:

Family history of premature cardiovascular disease (heart attack or stroke before age 55 in men, 65 in women)
Personal history of cardiovascular events, especially if they occurred despite “normal” cholesterol
Familial hypercholesterolemia (FH) or suspected FH
Recurrent cardiovascular events despite optimal statin therapy
Family history of elevated Lp(a)
Aortic valve stenosis, especially if diagnosed before age 65
Borderline cardiovascular risk where Lp(a) could reclassify your risk category

How the test works

The Lp(a) blood test is simple:

Fasting required? No — Lp(a) levels are not affected by recent meals
How often? Once is usually sufficient. Since Lp(a) is genetically determined, levels remain stable throughout life (with minor exceptions during acute illness, pregnancy, or menopause)
Cost: $30-80 USD (£25-65) in most countries, though coverage varies
Turnaround: 1-3 business days at most labs

Pro tip: Ask specifically for an Lp(a) test. It is NOT included in a standard lipid panel and must be ordered separately. Many doctors will only order it if you request it.

How to interpret your results

Understanding the two measurement units

Lp(a) is reported in two different units depending on the lab, and they are not directly interchangeable:

Unit	Low risk	Borderline	High risk	Very high risk
mg/dL (mass)	< 30	30-50	50-100	> 100
nmol/L (molar)	< 75	75-125	125-250	> 250

Important: The commonly used conversion factor of 2.5 (nmol/L ÷ 2.5 = mg/dL) is only a rough approximation. The actual ratio varies between individuals because Lp(a) particles differ in size. For clinical decisions, use the unit your lab reports and compare against that unit’s reference ranges.

What your numbers mean

Lp(a) below 30 mg/dL (75 nmol/L): Desirable. Your Lp(a) is not a significant contributor to your cardiovascular risk. No specific action needed regarding Lp(a), but continue managing other risk factors.

Lp(a) 30-50 mg/dL (75-125 nmol/L): Borderline. Mildly elevated. The added risk is modest but may become significant if combined with other risk factors like high LDL, high blood pressure, smoking, or diabetes.

Lp(a) 50-100 mg/dL (125-250 nmol/L): High. You carry a meaningfully elevated cardiovascular risk. Aggressive management of all other modifiable risk factors is strongly recommended.

Lp(a) above 100 mg/dL (250 nmol/L): Very high. Your lifetime cardiovascular risk is significantly elevated. Discuss comprehensive risk management with a cardiologist. Consider early coronary calcium scoring to assess whether plaque has already developed.

Context matters

A single number doesn’t tell the full story. Your Lp(a) result should be interpreted alongside:

Your overall lipid profile (LDL-C, HDL-C, triglyceride-to-HDL ratio)
Blood pressure and pulse pressure
Inflammatory markers like hs-CRP
ApoB levels — a more accurate measure of atherogenic particle count
Family history and lifestyle factors
Coronary artery calcium (CAC) score

Lp(a) and biological aging

The longevity connection

Lp(a) isn’t just a cardiovascular risk marker — it’s increasingly recognized as a contributor to accelerated biological aging. Here’s why:

Vascular aging acceleration. Elevated Lp(a) promotes arterial stiffness and calcification over time. This accelerates vascular aging, which is one of the strongest predictors of all-cause mortality. Your arteries may be decades “older” than your chronological age if Lp(a) has been silently promoting plaque buildup.

Inflammatory burden. The oxidized phospholipids on Lp(a) particles contribute to systemic chronic inflammation — the same “inflammaging” process that drives biological age acceleration. Studies show that people with high Lp(a) tend to have elevated hs-CRP and other inflammatory biomarkers.

Interaction with other aging biomarkers. Lp(a) doesn’t exist in isolation. It interacts with other biological aging systems:

High Lp(a) combined with insulin resistance (measured by TyG index or C-peptide) dramatically amplifies cardiovascular risk
Elevated Lp(a) worsens the impact of high homocysteine
The clot-promoting effect of Lp(a) compounds the risk from endothelial dysfunction

What the biological age algorithms say

Interestingly, Lp(a) is not included in the PhenoAge or KDM biological age algorithms — partly because it wasn’t routinely measured in the NHANES dataset used to develop them. However, researchers increasingly argue it should be integrated into next-generation aging clocks, especially for cardiovascular age estimation.

The takeaway: Even if your biological age from blood tests looks favorable, an elevated Lp(a) represents a hidden risk that those algorithms may miss. Testing Lp(a) fills a critical blind spot.

What you can do about high Lp(a)

The honest truth: lifestyle changes have minimal effect

Unlike LDL cholesterol, Lp(a) levels are resistant to most lifestyle interventions:

Diet changes: Minimal to no effect on Lp(a)
Exercise: No consistent evidence of Lp(a) reduction
Statins: May slightly increase Lp(a) (by 10-20%), though the net cardiovascular benefit of statins still outweighs this
Weight loss: Minimal effect

This genetic stubbornness is precisely why knowing your level matters — you can’t “fix” something you don’t know you have, and you need a different strategy than the standard lifestyle playbook.

What actually works

1. Aggressive management of all other risk factors

Since you can’t change Lp(a) with current approved therapies, the strategy is to minimize every risk factor you can control:

Lower LDL-C aggressively (target < 70 mg/dL / 1.8 mmol/L if Lp(a) is elevated)
Optimize blood pressure (target < 120/80 mmHg)
Maintain a healthy waist-to-hip ratio and body fat percentage
Eliminate smoking completely
Manage blood glucose and insulin sensitivity
Reduce inflammatory markers

2. Niacin (vitamin B3)

Extended-release niacin can lower Lp(a) by 20-30%. However, it fell out of favor after the AIM-HIGH and HPS2-THRIVE trials showed no additional cardiovascular benefit when added to statins. Some specialists still consider it in patients with very high Lp(a) on a case-by-case basis.

Consult your healthcare provider before starting any supplementation.

3. PCSK9 inhibitors

Evolocumab and alirocumab — injectable antibodies already approved for LDL lowering — also reduce Lp(a) by approximately 20-30%. Post-hoc analyses from the FOURIER and ODYSSEY OUTCOMES trials suggest that Lp(a) reduction contributes to their cardiovascular benefit.

4. Lipoprotein apheresis

For patients with very high Lp(a) (typically > 60 mg/dL) and progressive cardiovascular disease despite optimal therapy, lipoprotein apheresis — a dialysis-like blood filtering procedure — can acutely lower Lp(a) by 60-75%. It’s performed every 1-2 weeks and is available in specialized centers. Coverage varies by country.

5. Emerging therapies (the future looks promising)

For the first time, targeted Lp(a)-lowering drugs are in advanced clinical development:

Pelacarsen (Novartis): An antisense oligonucleotide (ASO) that reduces Lp(a) production in the liver by ~80%. Phase III results from the Lp(a)HORIZON trial are expected in 2025-2026.
Olpasiran (Amgen): A small interfering RNA (siRNA) that reduces Lp(a) by over 95% with quarterly injections. Phase III OCEAN(a) trial is ongoing.
Lepodisiran (Eli Lilly): Another siRNA showing >90% Lp(a) reduction with dosing as infrequent as every 24-48 weeks.

If these trials confirm cardiovascular benefit, Lp(a)-specific therapies could be available by 2027-2028 — making today’s Lp(a) test a powerful investment in your future health.

The information provided does not replace professional medical advice. Consult your healthcare provider before starting any supplementation or making treatment decisions.

How SuperAge helps you track cardiovascular risk

While Lp(a) itself requires a lab blood test, SuperAge helps you monitor the modifiable cardiovascular risk factors that become even more critical when Lp(a) is elevated:

Cardiovascular metrics from your wrist

SuperAge automatically tracks key cardiovascular indicators through Apple Watch and HealthKit:

Resting heart rate — a marker of cardiac fitness that correlates with longevity
Heart rate variability (HRV) — reflects autonomic nervous system health and stress resilience
Heart rate recovery — how quickly your heart rate drops after exercise, a powerful mortality predictor
VO2 max estimates — cardiorespiratory fitness, the single strongest predictor of cardiovascular mortality

Your biological age, contextualized

SuperAge calculates your biological age from multiple health metrics and shows you where you stand compared to population norms. If you know your Lp(a) is elevated, SuperAge’s biological age tracking becomes even more valuable — you can monitor whether your efforts to optimize every other risk factor are actually moving the needle on your overall health trajectory.

Blood test integration

With SuperAge 3.2, you can log your blood test results — including lipid panels, inflammatory markers, and metabolic biomarkers — to get a more complete picture of your health alongside your wearable data.

Frequently asked questions

Is Lp(a) included in a standard cholesterol test?

No. Lp(a) requires a separate, specific blood test. It is not part of a standard lipid panel. You typically need to ask your doctor to order it, or use a direct-to-consumer lab service. Most people go their entire lives without ever having Lp(a) measured.

Can I lower my Lp(a) with diet and exercise?

Unfortunately, diet and exercise have minimal to no effect on Lp(a) levels because they are ~90% genetically determined. However, a heart-healthy lifestyle is still critical — it reduces your overall cardiovascular risk, which is especially important when Lp(a) is elevated. Think of it as compensating for a risk factor you can’t directly change.

How often should I retest Lp(a)?

For most people, once is enough. Since Lp(a) is genetically fixed, your level remains stable throughout adult life. Exceptions: retest if your initial measurement was during an acute illness (which can temporarily lower Lp(a)), during pregnancy, or if you start a therapy specifically targeting Lp(a).

My Lp(a) is high but my coronary calcium score is zero — should I worry?

A zero CAC score is reassuring — it means significant plaque hasn’t developed yet. However, high Lp(a) means you’re at elevated lifetime risk. Continue aggressive prevention and consider repeating the CAC score every 5 years to detect early plaque formation. Think of high Lp(a) with zero CAC as “the gun is loaded but hasn’t fired yet.”

Does high Lp(a) mean I’ll definitely have a heart attack?

No. Elevated Lp(a) increases your probability of cardiovascular events, but many people with high Lp(a) live long, healthy lives — especially if they manage all other risk factors well. Conversely, some people with normal Lp(a) still have heart attacks due to other risk factors. Lp(a) is one piece of a complex puzzle.

Key takeaways

Lp(a) is a genetically determined cardiovascular risk factor that affects ~20% of the population and is not measured in standard cholesterol tests
One blood test is usually enough — levels are stable throughout life, so get tested once and know your status
Elevated Lp(a) increases risk of heart attack, stroke, and aortic valve disease independently of all other risk factors
Lifestyle changes don’t significantly lower Lp(a) — but aggressively managing every other risk factor is the best current strategy
Targeted therapies are in late-stage trials — pelacarsen, olpasiran, and lepodisiran may transform Lp(a) management by 2027-2028
Knowing your Lp(a) is an investment in your future — it fills a critical blind spot in standard cardiovascular screening

Take control of your cardiovascular health today

Your Lp(a) level is written in your DNA — but your response to it is entirely in your hands. Get tested, know your number, and take action on every risk factor you can control.

Ready to track your cardiovascular health? Download SuperAge and start monitoring your heart metrics, biological age, and blood biomarkers — all in one place.

References

Nordestgaard BG et al. — “Lipoprotein(a) as a cardiovascular risk factor: current status.” European Heart Journal (2010)
Tsimikas S et al. — “A Test in Context: Lipoprotein(a) — Diagnosis, Prognosis, Controversies, and Emerging Therapies.” JACC (2017)
Kronenberg F, Mora S et al. — “Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.” European Heart Journal (2022)
Kamstrup PR et al. — “Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.” JAMA (2009)
O’Donoghue ML et al. — “Small interfering RNA to lower lipoprotein(a) in cardiovascular disease.” NEJM (2023)
Burgess S et al. — “Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies.” JAMA Cardiology (2018)

Last updated: 2026-03-28. This article is regularly reviewed to ensure accuracy.